Literature DB >> 16237201

Emerging empirical evidence on the ethics of schizophrenia research.

Laura B Dunn1, Philip J Candilis, Laura Weiss Roberts.   

Abstract

Many challenging ethical questions come with the scientific efforts to understand the nature and treatment of schizophrenia. The empirical study of ethical aspects of schizophrenia research has sought to clarify and resolve many of these questions. In this article we provide an overview of the existing data-based literature on schizophrenia research ethics and outline directions for future inquiry. We examine 5 broad categories of inquiry into the ethics of schizophrenia research: (1) Scientific designs (eg, placebo-controlled studies and medication-free intervals, prodromal and high-risk research, and genetics research); (2) informed consent and decision-making capacity, including assessment of decisional abilities, as well as intervention studies; (3) understanding and perceptions of risk and benefit (including the therapeutic misconception); (4) influences on research participation (including voluntarism, altruism, and other motivations); and (5) key participant safeguards, such as protocol review and participant advocates. We discuss how empirical work in each of these areas answers certain questions and raises new ones. Finally, we highlight important gaps in our understanding of ethically relevant aspects of schizophrenia research and offer a specific research agenda for empirical ethics.

Entities:  

Mesh:

Year:  2005        PMID: 16237201      PMCID: PMC2632189          DOI: 10.1093/schbul/sbj012

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  214 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

Review 2.  Beyond the question of placebo controls: ethical issues in psychopharmacological drug studies.

Authors:  Ellen Frank; Danielle M Novick; David J Kupfer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

3.  Therapeutic misconception and the appreciation of risks in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Thomas Grisso; Michelle Renaud
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

4.  Perspectives on use and protection of genetic information in work settings: results of a preliminary study.

Authors:  Laura Weiss Roberts; Cynthia M A Geppert; Teddy D Warner; Katherine A Green Hammond; Melinda Rogers; Julienne Smrcka; Brian B Roberts
Journal:  Soc Sci Med       Date:  2005-04       Impact factor: 4.634

Review 5.  Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes?

Authors:  Wolfgang Maier; Barbara Höfgen; Astrid Zobel; Marcella Rietschel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

6.  Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation.

Authors:  L W Roberts; T D Warner; J L Brody
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

7.  Sense and nonsense: an essay on schizophrenia research ethics.

Authors:  W T Carpenter; R R Conley
Journal:  Schizophr Res       Date:  1999-02-15       Impact factor: 4.939

8.  Schizophrenic and medical inpatients as informed drug consumers.

Authors:  D A Soskis
Journal:  Arch Gen Psychiatry       Date:  1978-05

Review 9.  Schizophrenia.

Authors:  Kim T Mueser; Susan R McGurk
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  The burden of complex genetics in brain disorders.

Authors:  George R Uhl; Robert W Grow
Journal:  Arch Gen Psychiatry       Date:  2004-03
View more
  23 in total

1.  Screening for understanding of research in the inpatient psychiatry setting.

Authors:  Norval J Hickman; Judith J Prochaska; Laura B Dunn
Journal:  J Empir Res Hum Res Ethics       Date:  2011-09       Impact factor: 1.742

2.  Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit.

Authors:  Michael R Basso; Philip J Candilis; Jay Johnson; Courtney Ghormley; Dennis R Combs; Taeh Ward
Journal:  J Clin Exp Neuropsychol       Date:  2010-12       Impact factor: 2.475

3.  Do human subject safeguards matter to potential participants in psychiatric genetic research?

Authors:  Laura Weiss Roberts; Jane Paik Kim; Tenzin Tsungmey; Laura B Dunn
Journal:  J Psychiatr Res       Date:  2019-06-08       Impact factor: 4.791

4.  Ethics of medication-free research in schizophrenia.

Authors:  Donna T Chen; Jonathan D Moreno
Journal:  Schizophr Bull       Date:  2006-02-08       Impact factor: 9.306

5.  A direct comparison of research decision-making capacity: schizophrenia/schizoaffective, medically ill, and non-ill subjects.

Authors:  Philip J Candilis; Kenneth E Fletcher; Cynthia M A Geppert; Charles W Lidz; Paul S Appelbaum
Journal:  Schizophr Res       Date:  2008-02       Impact factor: 4.939

6.  Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.

Authors:  T Scott Stroup; Paul S Appelbaum; Hongbin Gu; Spencer Hays; Marvin S Swartz; Richard S E Keefe; Scott Y Kim; Theo C Manschreck; Roger A Boshes; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2011-05-10       Impact factor: 4.939

7.  Are individuals living with mental illness and their preferred alternative decision-makers attuned and aligned in their attitudes regarding treatment decisions?

Authors:  Laura Weiss Roberts; Jane Paik Kim
Journal:  J Psychiatr Res       Date:  2016-03-15       Impact factor: 4.791

8.  Ethics in Psychiatric Research: A Review of 25 Years of NIH-funded Empirical Research Projects.

Authors:  James Dubois; Holly Bante; Whitney B Hadley
Journal:  AJOB Prim Res       Date:  2011-12-06

9.  Giving voice to study volunteers: comparing views of mentally ill, physically ill, and healthy protocol participants on ethical aspects of clinical research.

Authors:  Laura Weiss Roberts; Jane Paik Kim
Journal:  J Psychiatr Res       Date:  2014-06-02       Impact factor: 4.791

10.  Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research.

Authors:  Laura B Dunn; Daniel S Kim; Ian E Fellows; Barton W Palmer
Journal:  Schizophr Bull       Date:  2008-02-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.